SCATTOLIN, DANIELA
 Distribuzione geografica
Continente #
NA - Nord America 261
EU - Europa 78
AS - Asia 60
SA - Sud America 4
Totale 403
Nazione #
US - Stati Uniti d'America 261
IT - Italia 31
SG - Singapore 31
CN - Cina 21
DE - Germania 11
SE - Svezia 11
GB - Regno Unito 7
FI - Finlandia 6
BR - Brasile 4
FR - Francia 4
IN - India 3
RU - Federazione Russa 3
NL - Olanda 2
TR - Turchia 2
HK - Hong Kong 1
IE - Irlanda 1
IQ - Iraq 1
LT - Lituania 1
PL - Polonia 1
UZ - Uzbekistan 1
Totale 403
Città #
Fairfield 42
Chandler 39
Santa Clara 15
Ashburn 14
Padova 14
Cambridge 13
Houston 12
Woodbridge 12
San Diego 8
Singapore 8
Ann Arbor 6
Helsinki 6
Seattle 6
Beijing 5
Boardman 5
Medford 5
New York 5
Princeton 5
Columbus 4
Des Moines 4
London 3
Milan 3
Amsterdam 2
Belluno 2
Castagnole 2
Dallas 2
Duncan 2
Falkenstein 2
Munich 2
Ogden 2
Pignone 2
Portland 2
Pune 2
Roxbury 2
Wilmington 2
Ankara 1
Brasília 1
Cabrobó 1
Dois Lajeados 1
Dublin 1
Guangzhou 1
Hong Kong 1
Hounslow 1
Kilburn 1
Los Angeles 1
Maida Vale 1
Nuremberg 1
Seregno 1
Shanghai 1
Sumaré 1
Surat 1
Tashkent 1
Torreglia 1
Xi'an 1
Zonguldak 1
Totale 280
Nome #
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 87
Clinical features and progression pattern of T790M+ compared with T790M-EGFR mutant NSCLC 87
1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI) 82
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 82
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 73
Totale 411
Categoria #
all - tutte 2.419
article - articoli 2.419
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.838


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20219 0 0 0 0 0 0 0 0 0 0 0 9
2021/2022155 3 16 34 4 9 24 25 4 6 4 8 18
2022/202389 11 14 5 11 6 8 1 8 20 3 2 0
2023/202467 9 6 11 4 3 16 6 1 3 3 3 2
2024/202591 0 5 12 7 25 4 1 19 18 0 0 0
Totale 411